Pfizer Inc. (NYSE:PFE) Stock Position Raised by BSW Wealth Partners

by · The Cerbat Gem

BSW Wealth Partners lifted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 1.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 51,824 shares of the biopharmaceutical company’s stock after buying an additional 619 shares during the quarter. BSW Wealth Partners’ holdings in Pfizer were worth $1,500,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in Pfizer in the first quarter worth about $315,000. Norden Group LLC lifted its position in shares of Pfizer by 26.8% during the 1st quarter. Norden Group LLC now owns 30,336 shares of the biopharmaceutical company’s stock worth $842,000 after buying an additional 6,404 shares during the period. Lincoln National Corp boosted its stake in Pfizer by 5.8% in the 1st quarter. Lincoln National Corp now owns 142,753 shares of the biopharmaceutical company’s stock valued at $3,961,000 after buying an additional 7,782 shares in the last quarter. Summit Financial Wealth Advisors LLC grew its position in Pfizer by 157.4% in the first quarter. Summit Financial Wealth Advisors LLC now owns 31,302 shares of the biopharmaceutical company’s stock valued at $869,000 after acquiring an additional 19,142 shares during the period. Finally, Blume Capital Management Inc. raised its stake in Pfizer by 33.7% during the first quarter. Blume Capital Management Inc. now owns 65,793 shares of the biopharmaceutical company’s stock worth $1,826,000 after acquiring an additional 16,568 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity

In related news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Trading Down 0.7 %

Pfizer stock traded down $0.21 during mid-day trading on Friday, hitting $28.09. The stock had a trading volume of 46,894,562 shares, compared to its average volume of 35,200,524. The stock has a market capitalization of $159.18 billion, a PE ratio of 37.96, a P/E/G ratio of 0.90 and a beta of 0.67. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock has a 50-day simple moving average of $29.03 and a two-hundred day simple moving average of $28.59.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.98%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PFE shares. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday. Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

Check Out Our Latest Stock Analysis on Pfizer

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).